Publication | Open Access
A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial
165
Citations
32
References
2019
Year
Ixekizumab was noninferior to guselkumab in complete skin clearance and superior in clearing nails at week 24. Ixekizumab cleared skin more rapidly in patients with moderate-to-severe plaque psoriasis, with a greater cumulative benefit, than guselkumab. Overall, the safety findings were consistent with the known safety profile for ixekizumab.
| Year | Citations | |
|---|---|---|
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial | 2017 | 838 |
2016 | 818 | |
2005 | 815 | |
2015 | 815 | |
2014 | 505 | |
2019 | 362 | |
2010 | 206 | |
2017 | 185 | |
2011 | 145 | |
2008 | 145 |
Page 1
Page 1